Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.46
    +2.34 (+0.31%)
     

  • GBP/EUR

    1.1672
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2472
    -0.0039 (-0.31%)
     

  • Bitcoin GBP

    50,897.34
    -507.47 (-0.99%)
     

  • CMC Crypto 200

    1,322.59
    -73.95 (-5.30%)
     

  • S&P 500

    5,100.23
    +51.81 (+1.03%)
     

  • DOW

    38,241.74
    +155.94 (+0.41%)
     

  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     

  • GOLD FUTURES

    2,348.10
    +5.60 (+0.24%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Roche's emicizumab haemophilia drug succeeds in trial

Reuters - UK Focus

ZURICH, Dec (Shanghai: 600875.SS - news) 22 (Reuters) - Roche Holding AG (IOB: 0QOK.IL - news) 's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday.

"The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment," it said in a statement, adding all secondary endpoints were also met.

Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910, which represents a threat to more traditional treatments from Novo Nordisk (LSE: 0QIU.L - news) and Shire (Xetra: S7E.DE - news) . (Reporting by Michael Shields)